Experimental cocktail targets Hard-to-Treat lymphomas
NCT ID NCT01846390
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of four drugs—romidepsin, gemcitabine, dexamethasone, and cisplatin—in 21 people with peripheral T-cell or diffuse large B-cell lymphoma who had already tried other treatments. The main goal was to find a safe dose of romidepsin when added to the standard GDP chemotherapy. Researchers also looked at side effects and whether the combo might work better than existing options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
romidepsin, gemcitabine, dexamethasone, cisplatin
What this could lead to
If successful, this could lead to a more effective chemotherapy combination for certain lymphomas, potentially improving survival.
What could go wrong
This is a very early Phase I trial with only 21 participants, focused on safety and dosing. It is too small to prove effectiveness, and side effects may be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7, Canada
-
Regional Health Authority B, Zone 2
Saint John, New Brunswick, E2L 4L2, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada